Targeting the crosstalk between metabolism and epigenetics to treat liver fibrosis [ 1/1/2021 - 12/31/2024 ]

Research Grant

Brief description Virtually all liver disease related morbidity and mortality is a consequence of fibrosis that culminates in liver failure or liver cancer. Since anti-fibrotic drugs are not available, new approaches to drug development are required. We have discovered a novel strategy for such drug development by modifying the expression of a specific gene (RARRES1) in a highly targeted manner and thereby interrupting the energy production that is needed by cells to drive fibrosis.

Funding Amount $1,032,259

Funding Scheme Ideas Grants

Chief Investigator A/Pr Mohammed Eslam

Notes Ideas Grants